

The logo for 2seventybio, featuring the text "2seventybio" in a dark blue, sans-serif font, with a green stylized "7" and a trademark symbol.

**\$125 Million**  
Follow-On Offering

The logo for SVB Securities, featuring the lowercase letters "svb" in a bold, dark blue font, followed by a blue chevron symbol pointing to the right, and the word "Securities" in a dark blue, sans-serif font.

Joint Bookrunner  
February 2023

## SVB Securities Serves as Joint Bookrunner for 2seventy bio's (Nasdaq: TSVT) Upsized \$125 Million Follow-On Offering

### Key Transaction Highlights

- Confidentially marketed deal that publicly launched and priced post-close February 28th
- Well oversubscribed from both new and existing investors
- Base deal upsized from \$100 million to \$125 million
- Deal consisted of 10,869,566 shares of common stock being sold at a public offering price of \$11.50 per share, which represents a 14.8% discount to last sale.
- 2seventy bio intends to use the net proceeds of this offering for research and development and clinical development costs to support the advancement of its product candidates and the expansion of research and development programs, advancement of the KarMMa trials to support the use of Abecma in earlier lines of therapy, pursuant to cost sharing arrangements with BMS, commercial activities in support of Abecma, working capital, capital expenditures, corporate development, and other general corporate purposes.
- This is SVB Securities' first bookrun offering for 2seventy bio and 7th bookrun equity offering in 2023.

If you would like to unsubscribe from this distribution, click [here](#). If you would like to unsubscribe from all SVB Securities distributions, click [here](#).

THIS EMAIL IS FOR INFORMATIONAL PURPOSES ONLY AND IS BEING FURNISHED TO INVESTMENT BANKING CLIENTS OF SVB SECURITIES LLC. THE INFORMATION INCLUDED HEREIN IS FOR YOUR INFORMATION ONLY AND MAY NOT BE REPRODUCED FOR OR REDISTRIBUTED TO ANY OTHER PURPOSES. THESE SECURITIES HAVE BEEN SOLD. THIS EMAIL IS NOT AN OFFER TO SELL, AND IS NOT SOLICITING AN OFFER TO BUY, ANY SECURITIES.

**BOSTON**

53 State Street  
40th Floor  
Boston, MA 02109

**CHARLOTTE**

2151 Hawkins Street  
Suite 1025  
Charlotte, NC 28203

**NASHVILLE**

40 Burton Hills Boulevard  
Suite 200  
Nashville, TN 37215

**NEW YORK**

1301 Avenue of the Americas  
12th Floor  
New York, NY 10019

**SAN FRANCISCO**

255 California Street  
12th Floor  
San Francisco, CA 94111